Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
Chimeric antigen receptor T-cell (CAR-T) therapy has been successful Partitions in creating extraordinary clinical outcomes in the treatment of hematologic malignancies including relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).With several FDA approvals, CAR-T therapy is recognized as an alternative treatment option for par